A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm

Background and Rationale: Systemic mastocytosis (SM) is a clonal hematologic neoplasm characterized by abnormal accumulation of mast cells which can lead to symptoms related to mast cell degranulation and/or, in the case of advanced systemic mastocytosis (AdvSM), organ dysfunction due to mast cell infiltration. AdvSM is a category of SM comprised of aggressive systemic mastocytosis (ASM), mast cell leukemia (MCL), and SM with an associated hematologic neoplasm (SM-AHN). Among these, SM-AHN is the most common subtype, accounting for approximately 70% of AdvSM.

A KIT D816V mutation found in up to 95% of SM cases is the primary oncogenic driver, making it a key therapeutic target. Avapritinib, a highly potent and selective inhibitor of D816V mutant KIT, has demonstrated high rates of rapid, deep, and durable responses in all AdvSM subtypes, including SM-AHN (Gotlib et al. Nature Medicine, 2021; DeAngelo et al., Nature Medicine, 2021). However, despite showing prolonged OS and low risk of progression of the SM component, some patients (20%) exhibit progression of the AHN component, including transformation to AML. In some patients, combination therapy with avapritinib and AHN-directed therapy may therefore be necessary for optimal control of SM-AHN. Hypomethylating agents (HMA) form the backbone of therapy for advanced myelodysplastic syndrome (MDS) and myelodysplastic/myeloproliferative neoplasm (MDS/MPN); hematologic neoplasms most likely to co-occur with SM in patients (pts) with SM-AHN. To date, the combination of HMA and KIT inhibitors has not been clinically evaluated. In this study, we aim to assess the safety and tolerability of the combination of avapritinib and decitabine in patients with SM-AHN.

Study design and Methods: The primary objective of the study is to establish the recommended dose (RP2D) of avapritinib in combination with decitabine based on dose-limiting toxicity, overall safety, and clinical activity data. A dose evaluation steering committee (DESC) comprised of participating investigators will review the totality of safety and efficacy data to determine RP2D. Secondary endpoints include SM overall response rate by the end of 6 cycles by the m-IWG consensus criteria and proposed ECNM-AIM criteria (Gotlib et al., J Allergy Clin Immunol Pract, 2022) and incidence/frequency of adverse events. Exploratory endpoints include patient reported outcomes, PFS, OS, and correlative biomarkers linked to mast cell disease or AHN.

Pts with a diagnosis of SM-AHN by the WHO 2022 criteria will be eligible for inclusion. Pts must have any of the following myeloid AHN per WHO 2022 criteria: MDS, CMML, MDS/MPN with neutrophilia, MDS/MPN with SF3B1 mutation and thrombocytosis, or MDS/MPN-NOS. Patients with MDS must have intermediate, high- or very-high risk by IPSS-R. Patients with very-low or low-risk MDS by IPSS-R must be intolerant/refractory to ESA or have serum EPO > 200 U/L. A baseline platelet count of ≥ 75 x 10⁹/L and ≥ 25 x 10⁹/L will be required for inclusion in the dose-finding and the dose-expansion phases, respectively. Key exclusion criteria include a diagnosis of AML, history of intracranial hemorrhage, prior treatment with avapritinib or decitabine with documented progression in SM or AHN component, respectively, or treatment with alternative KIT inhibitor or azacitidine within 4 weeks of study treatment initiation.

In the dose finding part of the study, a Bayesian adaptive design will be employed to assess different doses of avapritinib (50 to 200 mg PO daily) in combination with fixed doses of decitabine (oral decitabine/cedazuridine: 35/100 mg/day or intravenous decitabine: 20 mg/m²/day on days 1-5) in a 28-day treatment cycle. Close attention will be paid to treatment-emergent thrombocytopenia with protocol-driven treatment holds and dose modification strategies employed when platelet count drops below 50 x 10⁹/L. After RP2D is determined, an additional 10 patients will be enrolled in the dose expansion phase. Patients with platelet count ≥ 25 x 10⁹/L and < 75 x 10⁹/L, will receive lead-in dosing with decitabine or decitabine/cedazuridine with the ability to add avapritinib if sufficient platelet thresholds are achieved.

Planned correlative studies include serial single-cell multi-omics utilizing scDNA-seq and immunophenotyping to assess impact of combination treatment on a molecularly complex disease state.

This study is currently open to accrual (NCT06327685).

Kuykendall:PharmaEssentia: Honoraria; Incyte: Honoraria; Protagonist Therapeutics: Honoraria, Research Funding; Novartis: Research Funding. Tashi:Telios: Research Funding; Italfarmaco: Research Funding; CITI Biopharma: Honoraria; Cogent: Membership on an entity's Board of Directors or advisory committees, Research Funding; PharmaEssentia: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Blueprint: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Study Steering Committee, Research Funding. Rampal:Protagonist: Consultancy; Cogent: Consultancy; PharmaEssentia: Consultancy; Zentalis: Consultancy, Research Funding; Incyte Corporation: Consultancy, Research Funding; Celgene/BMS: Consultancy; Kartos: Consultancy; Galecto: Consultancy; Sierra Oncology/GSK: Consultancy; Sumitomo Dainippon: Consultancy; Ryvu: Research Funding; Blueprint: Consultancy; Jubilant: Consultancy; Constellation/MorphoSys: Consultancy, Research Funding; Karyopharm: Consultancy; CTI BioPharma: Consultancy; AbbVie: Consultancy; Stemline Therapeutics: Consultancy, Research Funding; Servier: Consultancy; Jazz Pharmaceuticals: Consultancy; Disc Medicine: Consultancy; Novartis: Consultancy; Promedior: Consultancy. Pettit:Sierra Oncology: Consultancy; Protagonist Therapeutics: Consultancy, Research Funding; Merck: Research Funding; Kura Oncology: Research Funding; AbbVie: Consultancy, Research Funding; Incyte: Consultancy; PharmaEssentia: Consultancy; Blueprint Medicines: Research Funding; BMS: Research Funding; Imago: Research Funding. Hoehn:Sobi Inc: Current Employment. Dimitrijevic:Blueprint Medicines Corporation: Current Employment, Current holder of stock options in a privately-held company. Komrokji:Jazz Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees; Taiho: Membership on an entity's Board of Directors or advisory committees; PharmaEssentia: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Servio: Honoraria; Geron: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy; Rigel: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sumitomo Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees; Keros: Membership on an entity's Board of Directors or advisory committees; Genentech: Consultancy; DSI: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS: Research Funding; Celgene/BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Servio: Membership on an entity's Board of Directors or advisory committees; CTI biopharma: Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Servier: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sobi: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; DSI: Honoraria, Membership on an entity's Board of Directors or advisory committees.